Page last updated: 2024-08-21

fluorobenzenes and Coronary Disease

fluorobenzenes has been researched along with Coronary Disease in 66 studies

Research

Studies (66)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.52)	18.7374
1990's	0 (0.00)	18.2507
2000's	43 (65.15)	29.6817
2010's	22 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boekholdt, SM; Kastelein, JJ; Khaw, KT; Rana, JS; Sondermeijer, BM; Wareham, NJ	1
Aksoy, Y; Senen, K; Sivri, N; Tekin, G; Yalta, K; Yetkin, E	1
Ge, J; Wang, Z	1
Ballantyne, CM; Cain, VA; Hoogeveen, RC; Karlson, BW; Palmer, MK; Raya, JL	1
Galeeva, ZM; Galiavich, AS	1
Blankenberg, S; Everett, BM; Glynn, RJ; Ridker, PM; Zeller, T	1
Kobalava, ZhD; Stavtseva, YV	1
Bybee, KA; Lavie, CJ; O'Keefe, JH	1
Ballantyne, CM; Cain, VA; Raichlen, JS	1
Henkin, Y	1
Capurso, A; Capurso, C; Colacicco, AM; D'Introno, A; Frisardi, V; Gadaleta, A; Panza, F; Santamato, A; Solfrizzi, V	1
Matsunaga, A; Miura, S; Nishikawa, H; Noda, K; Ogawa, M; Rainwater, DL; Saku, K; Shirai, K; Uehara, Y; Zhang, B	1
Clearfield, M; Kemp, R; Shah, BM	1
Chin, J	1
de Lorgeril, M	1
Abate, N; Ballantyne, CM; Catapano, AL; Davidson, MH; Polis, AB; Smugar, SS; Tershakovec, AM	1
Eren, M	1
Ferdinand, KC	1
Koenig, W; Ridker, PM	1
Blumenthal, RS; Harrington, C; Hasan, RK; Horne, A	1
Hu, M; Lee, MH; Mak, VW; Tomlinson, B	1
Avorn, J; Choudhry, NK; Glynn, RJ; Patrick, AR	1
Hlatky, M	1
Averna, M; Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Missault, L; Shah, A; Vaverkova, H; Viigimaa, M	1
Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA	1
Kones, R	1
Agatston, A; Blaha, MJ; Blankstein, R; Blumenthal, RS; Budoff, MJ; DeFilippis, AP; Lima, J; Nasir, K; O'Leary, DH; Rivera, JJ	1
Averna, M; Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Missault, L; Shah, A; Taggart, W; Vaverkova, H; Viigimaa, M	1
Schalkwijk, CG; Simsek, S; Wolffenbuttel, BH	1
Hitman, GA	1
Barbosa, SP; Bianco, HT; Fonseca, FA; França, CN; Izar, MC; Kasmas, SH; Mendes, GD; Pinheiro, LF; Povoa, RM	1
Iino, K; Ishida, M; Ito, H; Kosaka, T; Koyama, T; Nobori, K; Oguma, Y; Terata, Y; Watanabe, H; Yamazaki, D	1
Igel, M; Sudhop, T; von Bergmann, K	1
Gaw, A	1
Bolego, C; Catapano, AL; Cignarella, A; Paoletti, R; Poli, A	1
Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA	1
Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J	2
Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ	1
Stein, EA	2
Tuomilehto, J	1
Dunselman, P; Hjalmarson, A; Kjekshus, J; McMurray, J; Waagstein, F	1
Brady, AJ; Palmer, SJ; Ratcliffe, AE	1
Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C	1
Mason, P	1
Bloch, KD; Gannon, J; Lee, RT; Lian, Q; MacGillivray, C; Nasseri, BA; Picard, MH; Scherrer-Crosbie, M; Weinberg, EO	1
Rosenson, RS	1
Feely, J; Sigurdsson, EL; Strandberg, TE	1
Teramoto, T; Watkins, C	1
Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C	1
Bots, AF; Kastelein, JJ	1
Ballantyne, CM; Bertolami, M; Cain, VA; Hernandez Garcia, HR; Nul, D; Raichlen, JS; Stein, EA; Theroux, P; Weiss, R	1
Einecke, D	1
Gandhi, SK; Ghali, JK; Hassman, DR; Insull, W; Miller, E; Y As, JW	1
Deedwania, PC; Gold, A; Gupta, M; Stein, M; Ycas, J	1
Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R	1
Cannon, CP; Kumar, A	1
Ku, DD; Sun, X	1
Rahimtoola, SH	1
Asmar, R; Duffield, E; Faergeman, O; Hill, L; Sosef, F; Wiklund, O; Windler, E	1
Hallinen, T; Martikainen, J; Niskanen, L; Peura, P; Soini, E	1
Olsson, AG	2
Bell, V; Coe, J; Frishman, WH; Heilbrunn, S; Josephson, M; Osterle, S; Singh, B; Strom, J; Turlapaty, P; Viray, R	1

Reviews

20 review(s) available for fluorobenzenes and Coronary Disease

Article	Year
Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin. Clinical interventions in aging, 2014, Volume: 9 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Asian People; Atherosclerosis; China; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Young Adult	2014
Disappointing recent cholesterol-lowering drug trials: is it not time for a full reappraisal of the cholesterol theory? World review of nutrition and dietetics, 2009, Volume: 100 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
[The role of statins in the treatment of heart failure]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37, Issue:7 Topics: Cardiovascular Diseases; Coronary Disease; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides	2009
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug design, development and therapy, 2011, Volume: 5 Topics: Adult; Age Factors; Animals; Child; Coronary Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2011
Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. Journal of clinical pharmacology, 2002, Volume: 42, Issue:8 Topics: Acyl Coenzyme A; Coronary Disease; Enzyme Inhibitors; Fluorobenzenes; Hypolipidemic Agents; Pyrimidines; Quinolines; Rosuvastatin Calcium; Sulfonamides	2002
Primary prevention: a simple, effective means of risk reduction. International journal of clinical practice. Supplement, 2002, Issue:130 Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Fluorobenzenes; Humans; Multicenter Studies as Topic; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2002
Novel statins: pharmacological and clinical results. Cardiovascular drugs and therapy, 2002, Volume: 16, Issue:3 Topics: Animals; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Naphthalenes; Pyrimidines; Quinolines; Rosuvastatin Calcium; Sulfonamides	2002
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
The power of statins: aggressive lipid lowering. Clinical cardiology, 2003, Volume: 26, Issue:4 Suppl 3 Topics: Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2003
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia. Diabetes research and clinical practice, 2003, Volume: 61 Suppl 1 Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Metformin; Motor Activity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2003
The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS. International journal of clinical practice, 2003, Volume: 57, Issue:9 Topics: Coronary Disease; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Statistical; Monte Carlo Method; Pyrimidines; Rosuvastatin Calcium; State Medicine; Sulfonamides; United Kingdom	2003
Statins: can the new generation make an impression? Expert opinion on emerging drugs, 2004, Volume: 9, Issue:2 Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2004
Review of efficacy of rosuvastatin 5 mg. International journal of clinical practice, 2005, Volume: 59, Issue:1 Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2005
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention. Journal of interventional cardiology, 2007, Volume: 20, Issue:6 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional	2007
The year in valvular heart disease. Journal of the American College of Cardiology, 2008, Feb-19, Volume: 51, Issue:7 Topics: Animals; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Arabidopsis Proteins; Bioprosthesis; Body Surface Area; Catheterization; Cholesterol, LDL; Coronary Disease; Disease Progression; Echocardiography, Three-Dimensional; Endocarditis, Bacterial; Fluorobenzenes; Heart Valve Diseases; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mitral Valve Insufficiency; Mitral Valve Stenosis; Odds Ratio; Practice Guidelines as Topic; Prosthesis Design; Prosthesis Fitting; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome; Tricuspid Valve Insufficiency; Ventricular Dysfunction, Left	2008
Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin. The American journal of cardiology, 2001, Mar-08, Volume: 87, Issue:5A Topics: Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Prognosis; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2001
A new statin: a new standard. Clinical cardiology, 2001, Volume: 24, Issue:8 Suppl Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Administration Schedule; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Quality of Health Care; Rosuvastatin Calcium; Sulfonamides	2001
Managing dyslipidemia in the high-risk patient. The American journal of cardiology, 2002, Mar-07, Volume: 89, Issue:5A Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States	2002

Trials

21 trial(s) available for fluorobenzenes and Coronary Disease

Article	Year
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis, 2014, Volume: 232, Issue:1 Topics: Absorption; Adult; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Pyrimidines; Risk; Rosuvastatin Calcium; Simvastatin; Sitosterols; Sulfonamides; Treatment Outcome	2014
[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. Terapevticheskii arkhiv, 2014, Volume: 86, Issue:9 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Essential Hypertension; Female; Fluorobenzenes; Humans; Hypertension; Hypolipidemic Agents; Lipid Metabolism; Lisinopril; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2014
High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation, 2015, May-26, Volume: 131, Issue:21 Topics: Aged; Angina, Unstable; Biomarkers; Cholesterol, HDL; Comorbidity; Coronary Disease; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Primary Prevention; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Troponin T	2015
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvas Journal of the American College of Cardiology, 2008, Aug-19, Volume: 52, Issue:8 Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk Metabolic syndrome and related disorders, 2009, Volume: 7, Issue:6 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. European heart journal, 2011, Volume: 32, Issue:1 Topics: Aged; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides	2011
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. Clinical biochemistry, 2011, Volume: 44, Issue:8-9 Topics: Aged; Apolipoproteins B; Azetidines; Cholesterol; Coronary Disease; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2011
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Diabetes & vascular disease research, 2011, Volume: 8, Issue:4 Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Combinations; Drug Substitution; Europe; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Odds Ratio; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2011
Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study. Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:5 Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Fasting; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2012
Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids in health and disease, 2013, Feb-04, Volume: 12 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Drug Combinations; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Serum Amyloid P-Component; Sulfonamides; Tumor Necrosis Factor-alpha	2013
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. American heart journal, 2004, Volume: 147, Issue:4 Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides	2004
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clinical therapeutics, 2004, Volume: 26, Issue:11 Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2004
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. International journal of cardiology, 2005, Apr-20, Volume: 100, Issue:2 Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2005
Achieving lipid goals in real life: the Dutch DISCOVERY study. International journal of clinical practice, 2005, Volume: 59, Issue:12 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides	2005
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. American heart journal, 2006, Volume: 151, Issue:5 Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2006
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clinic proceedings, 2007, Volume: 82, Issue:5 Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Creatinine; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Managed Care Programs; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2007
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). The American journal of cardiology, 2007, Jun-01, Volume: 99, Issue:11 Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoprotein A-I; Asian People; Atorvastatin; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States	2007
Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology, 2008, Volume: 111, Issue:4 Topics: Aged; Atorvastatin; Canada; Cholesterol, LDL; Coronary Disease; European Union; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2008

Other Studies

28 other study(ies) available for fluorobenzenes and Coronary Disease

Article	Year
Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study. European heart journal, 2013, Volume: 34, Issue:18 Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; England; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Patient Selection; Prospective Studies; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides	2013
Statins decrease mean platelet volume irrespective of cholesterol lowering effect. Kardiologia polska, 2013, Volume: 71, Issue:10 Topics: Adult; Atorvastatin; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Mean Platelet Volume; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides	2013
[The Efficacy and Safely of Rosuvastatin in Patients With Coronary Heart Disease]. Kardiologiia, 2015, Volume: 55, Issue:11 Topics: Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2015
Intensive lipid intervention in the post-ENHANCE era. Mayo Clinic proceedings, 2008, Volume: 83, Issue:8 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
Re-evaluating therapeutic target goals for statin-treated patients: time for revolutionary changes? Journal of the American College of Cardiology, 2008, Aug-19, Volume: 52, Issue:8 Topics: Apolipoproteins B; Cholesterol, LDL; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides	2008
Beyond coronary artery disease: rosuvastatin in older patients with ischemic systolic heart failure. Journal of the American Geriatrics Society, 2008, Volume: 56, Issue:7 Topics: Aged; Cholesterol; Coronary Disease; Dementia; Fluorobenzenes; Geriatrics; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Ventricular Dysfunction, Left	2008
Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study. Journal of lipid research, 2009, Volume: 50, Issue:9 Topics: Apolipoproteins; Biomarkers; Cholesterol; Cholesterol, HDL; Coronary Disease; Electrophoresis, Capillary; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Inflammation; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2009
Using statins to treat 'healthy' patients: are we there yet? Expert review of pharmacoeconomics & outcomes research, 2009, Volume: 9, Issue:2 Topics: Clinical Trials as Topic; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Costs; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Preventive Medicine; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2009
The role of C-reactive protein (CRP) and statin treatment in reducing cardiovascular risk. South Dakota medicine : the journal of the South Dakota State Medical Association, 2009, Volume: 62, Issue:3 Topics: C-Reactive Protein; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2009
Achieving treatment goals in low-risk, asymptomatic patients. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:4 Suppl 4 Topics: Albuminuria; Antihypertensive Agents; Biomarkers; Black or African American; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Health Status Indicators; Humans; Hypolipidemic Agents; Metabolic Syndrome; Middle Aged; Obesity; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; United States	2010
Statin therapy in primary prevention: new insights regarding women and the elderly. The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9 Topics: Age Factors; Aged; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sex Factors; Sulfonamides; United States	2010
Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily). The American journal of cardiology, 2010, Dec-01, Volume: 106, Issue:11 Topics: Aged; C-Reactive Protein; China; Cholesterol, HDL; Coronary Disease; DNA; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Nephelometry and Turbidimetry; Obesity, Abdominal; Polymorphism, Genetic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2010
The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. Journal of the American College of Cardiology, 2011, Feb-15, Volume: 57, Issue:7 Topics: C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides	2011
The cost-effectiveness of rosuvastatin therapy JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Journal of the American College of Cardiology, 2011, Feb-15, Volume: 57, Issue:7 Topics: Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides	2011
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients. The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2011
Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet (London, England), 2011, Aug-20, Volume: 378, Issue:9792 Topics: Aged; Aged, 80 and over; C-Reactive Protein; Calcium; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Survival Analysis; Tomography, X-Ray Computed	2011
Statins and glycaemic control--a cause for concern? Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:5 Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2012
Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease. International journal of cardiology, 2012, Jun-28, Volume: 158, Issue:1 Topics: Cardiovascular Diseases; Clopidogrel; Coronary Disease; Drug Interactions; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ticlopidine	2012
The statin wars. Lancet (London, England), 2003, Nov-29, Volume: 362, Issue:9398 Topics: Coronary Disease; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2003
Update on statins. Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing, 2004, Volume: 22, Issue:2 Topics: Atorvastatin; Coronary Disease; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2004
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003. Atherosclerosis. Supplements, 2004, Volume: 5, Issue:3 Topics: Atorvastatin; Coronary Disease; Fluorobenzenes; Goals; Heptanoic Acids; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2004
Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion. American journal of physiology. Heart and circulatory physiology, 2005, Volume: 288, Issue:4 Topics: Animals; Coronary Disease; Fluorobenzenes; Heart Ventricles; Hematopoietic Stem Cell Mobilization; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligation; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrimidines; RNA, Messenger; Rosuvastatin Calcium; Stem Cells; Sulfonamides	2005
[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?]. MMW Fortschritte der Medizin, 2006, Jun-15, Volume: 148, Issue:24 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Placebos; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional	2006
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. The American journal of geriatric pharmacotherapy, 2007, Volume: 5, Issue:3 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2007
Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. American journal of physiology. Heart and circulatory physiology, 2008, Volume: 294, Issue:2 Topics: Animals; Blood Pressure; Blotting, Western; Body Weight; Coronary Disease; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Nitric Oxide; Organ Size; Poisons; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides	2008
Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Current medical research and opinion, 2008, Volume: 24, Issue:6 Topics: Atorvastatin; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Finland; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Expectancy; Male; Markov Chains; Middle Aged; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
[60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high]. MMW Fortschritte der Medizin, 2001, Nov-01, Volume: 143, Issue:44 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors	2001
Hemodynamic effects of flestolol, a titratable short-acting intravenous beta-adrenergic receptor blocker. Journal of clinical pharmacology, 1988, Volume: 28, Issue:3 Topics: Adrenergic beta-Antagonists; Adult; Aged; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heart Ventricles; Hemodynamics; Humans; Male; Middle Aged; Propanolamines	1988